Description： IMPACT has discovered two series of novel small molecular microtubule inhibitors, and selected IMP3138 as a clinical candidate for further development. In comparison with the most commonly used anti-cancer drugs paclitaxel, IMP3138 has following advantages: simple structure, easy to synthesize, good aqueous solubility, high in vitro activity, and good in vivo efficacy in several animal cancer models. Importantly, IMP3138 is highly active against multidrug-resistant tumor cells. In addition, IMP3138 has an amino group which can be used for the preparation of antibody drug conjugate (ADC).
IP： Two patent applications have been filed for our novel microtubule inhibitors.
Future Plan： IMPACT is seeking partners and investors to accelerate the clinical development of its microtubule inhibitors, as well as the development of ADC.